Pomerantz Law Firm Announces the Filing of a Class Action against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation and Certain Officers - IMVT; HSACU; HSAC; and HSACW

NEW YORK, Feb. 20, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation ("HSAC", "Immunovant", or the "Company") (NASDAQ: IMVT; HSACU; HSAC; and HSACW) and certain of its officers.A A  The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 21-cv-00918, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Immunovant securities between October 2, 2019 and February 1, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.If you are a shareholder who purchased Immunovant securities during the Class Period, you have until April 20, 2021A to ask the Court to appoint you as Lead Plaintiff for the class.A  A copy of the Complaint can be obtained at A  To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.comA or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.A  [Click here for information about joining the class action]Immunovant is a clinical-stage biopharmaceutical company that develops monoclonal antibodies for the treatment of autoimmune diseases.A  The Company is developing IMVT-1401, a novel fully human monoclonal antibody, which is in Phase II a clinical trials for the treatment of myasthenia gravis and thyroid eye disease ("TED"), also known as Graves' ophthalmopathy.A  The Company has also completed initiation of Phase II clinical trials of IMVT-1401 for the treatment of warm autoimmune hemolytic anemia ("WAIHA").On September 29, 2019, HSAC, then a blank check company, also known as a special purpose acquisition company, entered into an agreement with Immunovant Sciences Ltd. ("Legacy Immunovant"), a private biopharmaceutical company, and shareholders of Legacy Immunovant, to effect a merger between the two entities (the "Merger").A  As a result of the Merger, HSAC acquired all of the issued and outstanding shares of Legacy Immunovant, and Legacy Immunovant became a wholly owned subsidiary of HSAC.A  Upon the closing of the Merger, HSAC changed its name to "Immunovant, Inc."
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Апрель 2021    »